Aclaris Therapeutics, Inc. — Form D/A

Aclaris Therapeutics, Inc. of MALVERN, PA, a company, filed a Form D amendment with the SEC on 2018-08-13. The offering totals $12.5M, of which $10.0M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (38)

Showing 25 of 38 people.

NameRoleLocation
William A HumphriesDirectorWayne, PA
Anand A MehraDirectorWayne, PA
Christopher A MolineauxDirectorWayne, PA
Andrew A PowellDirectorWayne, PA
Bryan A ReasonsDirectorWayne, PA
Andrew A SchiffDirectorWayne, PA
Stephen A TullmanDirectorWayne, PA
Brett A FairExecutive OfficerWayne, PA
Christopher PowalaExecutive OfficerMalvern, PA
Stuart ShanlerExecutive OfficerMalvern, PA
David GordonExecutive OfficerAustin, TX
Joseph MonahanExecutive OfficerSt. Louis, MO
Hugh DavisDirectorWest Palm Beach, FL
Hugh DavisExecutive OfficerWest Palm Beach, FL
Andrew SchiffDirectorNew York, NY
Anand MehraDirectorWayne, PA
James LoeropExecutive OfficerWayne, PA
Neal WalkerDirectorMalvern, PA
Neal WalkerExecutive OfficerMalvern, PA
Vincent MilanoDirectorWayne, PA
William HumphriesDirectorWayne, PA
Kevin BalthaserExecutive OfficerWayne, PA
Christopher MolineauxDirectorWynnewood, PA
Maxine GowenDirectorWayne, PA
Ketan PatelDirectorCambridge, MA

Other filings by this issuer (7)

FiledFormOfferingSold
2024-12-04D$80.0M$80.0M
2020-04-08D$11.4M$11.0M
2017-08-14D$12.5M$10.0M
2016-06-14D$20.0M$20.0M
2015-09-11D$40.0M$40.0M
2014-10-08D$21.3M$10.6M
2012-09-10D$20.9M$20.9M

More